Embecta Corp. $EMBC Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC lowered its stake in Embecta Corp. (NASDAQ:EMBC) by 76.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,427 shares of the company’s stock after selling 64,090 shares during the period. Hsbc Holdings PLC’s holdings in Embecta were worth $246,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of EMBC. American Century Companies Inc. raised its position in Embecta by 16.9% in the 1st quarter. American Century Companies Inc. now owns 3,813,411 shares of the company’s stock valued at $48,621,000 after purchasing an additional 551,477 shares in the last quarter. Deerfield Management Company L.P. Series C raised its position in Embecta by 19.8% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 3,270,535 shares of the company’s stock valued at $67,537,000 after purchasing an additional 540,192 shares in the last quarter. Jefferies Financial Group Inc. raised its position in Embecta by 60.1% in the 1st quarter. Jefferies Financial Group Inc. now owns 573,000 shares of the company’s stock valued at $7,306,000 after purchasing an additional 215,000 shares in the last quarter. Russell Investments Group Ltd. raised its position in Embecta by 382.9% in the 1st quarter. Russell Investments Group Ltd. now owns 262,541 shares of the company’s stock valued at $3,347,000 after purchasing an additional 208,170 shares in the last quarter. Finally, Nuveen LLC purchased a new position in shares of Embecta in the 1st quarter valued at about $2,314,000. Institutional investors and hedge funds own 93.83% of the company’s stock.

Embecta Stock Up 1.3%

NASDAQ:EMBC opened at $14.49 on Friday. The stock’s 50 day moving average price is $11.79 and its 200 day moving average price is $11.90. The company has a market capitalization of $847.52 million, a PE ratio of 10.13, a P/E/G ratio of 0.79 and a beta of 1.12. Embecta Corp. has a 52-week low of $9.20 and a 52-week high of $21.48.

Embecta (NASDAQ:EMBC) last released its quarterly earnings results on Friday, August 8th. The company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.35. The firm had revenue of $295.50 million for the quarter, compared to the consensus estimate of $278.15 million. Embecta had a negative return on equity of 23.40% and a net margin of 7.58%.The firm’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.74 EPS. Embecta has set its FY 2025 guidance at 2.900-2.950 EPS. As a group, sell-side analysts anticipate that Embecta Corp. will post 2.85 EPS for the current fiscal year.

Embecta Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 15th. Shareholders of record on Friday, August 29th will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 4.1%. The ex-dividend date of this dividend is Friday, August 29th. Embecta’s dividend payout ratio (DPR) is presently 41.96%.

Wall Street Analysts Forecast Growth

EMBC has been the topic of a number of recent analyst reports. Zacks Research upgraded Embecta from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 26th. Mizuho dropped their price objective on Embecta from $13.00 to $12.00 and set a “neutral” rating on the stock in a report on Wednesday, July 16th. Wall Street Zen upgraded Embecta from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. Finally, BTIG Research set a $25.00 price objective on Embecta and gave the company a “buy” rating in a report on Friday, May 23rd. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

Embecta Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.